Navigation Links
Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties' Misleading Patent Assertions
Date:12/19/2011

imary brain cancer.  It does not include any of the myriad other types of cancers.    

Linda Powers, CEO of Northwest Bio, commented that "We want to correct the misleading statements about patents that have been made by certain parties with a vested interest in slowing us down.  We have confirmed our analysis with patent experts at leading national law firms, and received supporting opinions from them.  We plan to continue correcting misleading statements by other parties, and we urge anyone who is interested in confirming the true facts to review the entire 8-year record of the Cedars Sinai/IMUC '090 patent application process, and the USPTO rejections.  The entire record is publicly available to all online from the USPTO." 

Powers concluded by stating that "We are justifiably confident that we do not infringe the '090 patent, and are prepared to assert all of our rights and remedies.  The '090 patent is neither a barrier nor even a speed bump in the way of our development and future commercialization of DCVax."

About Northwest Biotherapeutics

NW Bio is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis in both the US and Europe.  The Company has a broad platform technology for dendritic cell-based vaccines.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  For further information
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Latin ... the market in Latin America with analysis and forecast ... in 2013, and is expected to reach $2,366.8 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
(Date:10/19/2014)... Asian Automatic patient billing report defines and segments the ... The Automatic patient billing market in Asia is estimated ... a developing CAGR of 7.2% from 2013 to 2018. ... patient billing market, to get an idea of the ... the segmentation of this market in the same region, ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... 11 Genta,Incorporated (Nasdaq: GNTA ) announced ... institutional investors to sell 6 million shares,of common ... totaling,approximately $3.1 million before fees and expenses. The ... February 13, 2008, subject to the,satisfaction of customary ...
... over Same Quarter Last Year - ... - FY08 Revenue Guidance Raised - - ... MINNEAPOLIS, Feb. 11 Uroplasty, Inc. (Amex:,UPI), a medical device company ... dysfunction,today reported record net sales of $3.7 million for the third quarter ...
... This week, Summit VetPharm,identified the first instance ... Vectra 3D(TM) flea and tick product. This situation,where ... popular website targeting,pet owners, is a clear violation ... after confirming the identity of the California,veterinarian, swiftly ...
Cached Biology Technology:Genta Announces Common Stock Offering of Approximately $3.1 Million 2Genta Announces Common Stock Offering of Approximately $3.1 Million 3Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 2Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 3Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 4Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 5Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 6Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 7Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 8Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 9Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 10Summit VetPharm Addressed Veterinarian Diverted Vectra 3D(TM) 2Summit VetPharm Addressed Veterinarian Diverted Vectra 3D(TM) 3
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... the structure of unknown natural compounds is a slow ... but this may now change thanks to a new ... University of California, San Diego and presented at RECOMB ... in Singapore. UC San Diego researchers have devised ...
... have just confirmed what poets have known for centuries: eyes ... brain. In a new study published in the April 2008 ... Harvard researchers describe the development of gene probe eye ... detect tissue repair in the brain of living organisms using ...
... known that the left and right sides of the brain ... influence cognitive performance and social behaviour. For instance, in humans, ... processing whereas the right side is better at comprehending musical ... work in the open access journal Neural Development have pinpointed ...
Cached Biology News:UC San Diego researchers eliminate drug discovery bottleneck 2UC San Diego researchers eliminate drug discovery bottleneck 3UC San Diego researchers eliminate drug discovery bottleneck 4Harvard researchers publish MRI images of genes in action in the living brain 2Neurons hard wired to tell left from right 2
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
Cell Culture Flask, 75 cm, treated polystyrene...
Cell Culture Flask, 75 cm, nontreated polystyrene...
... virtually every research laboratory, the revolutionary Luminex ... accurately, inexpensively and in real time enhancing ... analysis system includes the Luminex 100, the ... xMAP technology which enables you to simultaneously ...
Biology Products: